Contemporary management of pemphigus

Bibliography

• Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006;355:1800-10
   PubMed Web of Science ®Google Scholar
• Langan SM, Smeeth L, Hubbard R, Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ 2008; doi: 10.1136/bmj.a180
   Google Scholar
• Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol 2011 29:432-6
   Google Scholar
• Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2012; doi: 10.1016/S0140-6736(12)61140-4
   Google Scholar
• Amagai M, Stanley JR. Desmoglein as a target in skin disease and beyond. J Invest Dermatol 2012;132:776-84
   PubMed Web of Science ®Google Scholar
• Anhalt GJ, Kim SC, Stanley JR, Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323:1729-35
   PubMed Web of Science ®Google Scholar
• Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006;39:617-30
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Bahmer F, Rose C, Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010;8:598-606
   PubMed Web of Science ®Google Scholar
• Leger S, Picard D, Ingen-Housz-Oro S, Prognostic factors of paraneoplastic pemphigus. Arch Dermatol 2012; doi: 10.1001/archdermatol.2012.1830
   Google Scholar
• Nishikawa T, Hashimoto T. Dermatoses with intraepidermal IgA deposits. Clin Dermatol 2000;18:315-18
   Google Scholar
• Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010;10:84-9
   PubMed Web of Science ®Google Scholar
• Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges 2011;9:927-47
   Google Scholar
• Harman KE, Seed PT, Gratian MJ, The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001;144:775-80
   PubMed Web of Science ®Google Scholar
• Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002;147:261-5
   PubMedGoogle Scholar
• Schmidt E, Dahnrich C, Rosemann A, Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 2010;19:458-63
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996;132:203-12
   PubMed Web of Science ®Google Scholar
• Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-37
   PubMed Web of Science ®Google Scholar
• Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin 2011;29:607-12
   Google Scholar
• Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology 2012;51:1145-53
   PubMed Web of Science ®Google Scholar
• Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol 1990;29:363-7
   PubMed Web of Science ®Google Scholar
• Vermaat H, Kirtschig G. Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice. Int J Dermatol 2008;47:737-42
   Google Scholar
• Alavi A, Lowe J, Walsh S, Corticosteroid-induced hyperglycemia is increased 10-fold in patients with pemphigus. Int J Dermatol 2012;51:1248-52
   Google Scholar
• Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol 2002;16:353-6
   PubMed Web of Science ®Google Scholar
• Mentink LF, Mackenzie MW, Toth GG, Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006;142:570-6
   PubMedGoogle Scholar
• Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000;136:868-72
   PubMedGoogle Scholar
• Chrysomallis F, Ioannides D, Teknetzis A, Treatment of oral pemphigus vulgaris. Int J Dermatol 1994;33:803-7
   PubMed Web of Science ®Google Scholar
• Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007;57:622-8
   PubMed Web of Science ®Google Scholar
• Werth VP, Fivenson D, Pandya AG, Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol 2008;144:25-32
   PubMedGoogle Scholar
• Beissert S, Mimouni D, Kanwar AJ, Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010;130:2041-8
   PubMed Web of Science ®Google Scholar
• Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol 2012;26:855-60
   Google Scholar
• Meggitt SJ, Anstey AV, Mohd Mustapa MF, British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011;165:711-34
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62
   PubMed Web of Science ®Google Scholar
• Newman WG, Payne K, Tricker K, A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 2011;12:815-26
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Luna M, Mate J, Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006;53:399-404
   Google Scholar
• Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51:143-6
   PubMed Web of Science ®Google Scholar
• Dejaco C, Mittermaier C, Reinisch W, Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001;121:1048-53
   PubMed Web of Science ®Google Scholar
• Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010;16:881-95
   PubMed Web of Science ®Google Scholar
• Beissert S, Werfel T, Frieling U, A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006;142:1447-54
   PubMed Web of Science ®Google Scholar
• Rose E, Wever S, Zillikens D, Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges 2005;3:200-6
   PubMedGoogle Scholar
• Martin LK, Werth V, Villanueva E, Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; doi: 10.1002/14651858.CD006263.pub2
   Google Scholar
• Jones EL, Epinette WW, Hackney VC, Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975;65:537-42
   PubMed Web of Science ®Google Scholar
• Lynch WS, Roenigk HH Jr. Mycophenolic acid for psoriasis. Arch Dermatol 1977;113:1203-8
   PubMedGoogle Scholar
• The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37
   PubMed Web of Science ®Google Scholar
• Sokumbi O, El-Azhary RA, Langman LJ. Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases. J Am Acad Dermatol 2012; doi: 10.1016/j.jaad.2012.07.003
   Google Scholar
• Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999;135:54-6
   PubMed Web of Science ®Google Scholar
• Allison AC, Kowalski WJ, Muller CJ, Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993;25:67-70
   PubMed Web of Science ®Google Scholar
• Senda M, DeLustro B, Eugui E, Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995;60:1143-8
   PubMed Web of Science ®Google Scholar
• Blaheta RA, Leckel K, Wittig B, Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999;31:1250-2
   PubMed Web of Science ®Google Scholar
• Morath C, Schwenger V, Beimler J, Antifibrotic actions of mycophenolic acid. Clin Transplant 2006;20 Suppl 17:25-9
   Google Scholar
• Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Immunol Allergy Clin North Am 2012;32:309-15
   Google Scholar
• Pavlovic AM, Bonaci-Nikolic B, Kozic D, Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus 2012;21:100-2
   Google Scholar
• Sollinger H. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc 2004;36:517S-20S
   PubMed Web of Science ®Google Scholar
• Bongiorno MR, Pistone G, Doukaki S, Arico M. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus. Int J Dermatol 2010;49:693-9
   PubMed Web of Science ®Google Scholar
• van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005;80:S244-53
   PubMed Web of Science ®Google Scholar
• van Gelder T, Le Meur Y, Shaw LM, Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:145-54
   PubMed Web of Science ®Google Scholar
• Baratta A, Camarillo D, Papa C, Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF). Pediatr Dermatol 2012; doi: 10.1111/j.525-470.2012.01730.x
   Google Scholar
• Hashimoto T, Kawakami T, Koga H, Therapeutic effect of mizoribine on pemphigus vulgaris and pemphigus foliaceus. Dermatol Ther 2012;25:382-5
   Google Scholar
• McCune WJ, Golbus J, Zeldes W, Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31
   PubMed Web of Science ®Google Scholar
• Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988;37:301-55
   PubMed Web of Science ®Google Scholar
• Marder W, McCune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med 2007;28:398-417
   PubMed Web of Science ®Google Scholar
• Pasricha JS. Current regimen of pulse therapy for pemphigus: minor modifications, improved results. Indian J Dermatol Venereol Leprol 2008;74:217-21
   Google Scholar
• Sethy PK, Khandpur S, Sharma VK. Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris. Indian J Dermatol Venereol Leprol 2009;75:476-82
   Google Scholar
• Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol 2012;30:78-83
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol 2012;30:84-94
   PubMed Web of Science ®Google Scholar
• Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011;7:349-59
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55
   PubMed Web of Science ®Google Scholar
• Li N, Zhao M, Hilario-Vargas J, Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005;115:3440-50
   PubMed Web of Science ®Google Scholar
• Aoyama Y. What's new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus. J Dermatol 2010;37:239-45
   Google Scholar
• Mimouni D, Blank M, Payne AS, Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol 2010;162:543-9
   PubMed Web of Science ®Google Scholar
• Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol 2006;6:600-6
   PubMed Web of Science ®Google Scholar
• Amagai M, Ikeda S, Shimizu H, A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009;60:595-603
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Gurcan HM. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol 2011;25:1073-9
   Google Scholar
• Enk A; European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009;19:90-8
   PubMed Web of Science ®Google Scholar
• Enk A, Fierlbeck G, French L, Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges 2009;7:806-12
   Google Scholar
• Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutan Med Surg 2006;10:205-21
   PubMed Web of Science ®Google Scholar
• el-Darouti M, Marzouk S, Abdel Hay R, The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol 2009;161:313-19
   PubMed Web of Science ®Google Scholar
• Hasko G, Szabo C, Nemeth ZH, Deitch EA. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 2001;103:473-8
   PubMed Web of Science ®Google Scholar
• Moller DR, Wysocka M, Greenlee BM, Inhibition of human interleukin-12 production by pentoxifylline. Immunology 1997;91:197-203
   PubMed Web of Science ®Google Scholar
• Gonzalez-Espinoza L, Rojas-Campos E, Medina-Perez M, Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transplant 2012;27:2023-8
   PubMed Web of Science ®Google Scholar
• D'Auria L, Bonifati C, Mussi A, Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997;8:383-7
   PubMed Web of Science ®Google Scholar
• Alecu M, Alecu S, Coman G, ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients. Roum Arch Microbiol Immunol 1999;58:121-30
   PubMedGoogle Scholar
• Feliciani C, Toto P, Amerio P, In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000;114:71-7
   PubMed Web of Science ®Google Scholar
• Lopez-Robles E, Avalos-Diaz E, Vega-Memije E, TNFalpha and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001;40:185-8
   PubMed Web of Science ®Google Scholar
• Pardo J, Mercader P, Mahiques L, Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005;153:222-3
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Schmidt E. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis? G Ital Dermatol Venereol 2009;144:339-49
   PubMed Web of Science ®Google Scholar
• Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009;8:940-3
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Garcia MS, Rehmus W, Kimball AB. A pilot study of etanercept treatment for pemphigus vulgaris. Arch Dermatol 2011;147:117-18
   PubMedGoogle Scholar
• Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 2010;63:925-46
   PubMedGoogle Scholar
• Busing V, Kern JS, Bruckner-Tuderman L, Hofmann SC. Recalcitrant pemphigus vulgaris responding to systemic tacrolimus. Dermatology 2010;221:122-6
   PubMed Web of Science ®Google Scholar
• Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45:420-34
   PubMed Web of Science ®Google Scholar
• Miyachi Y. Pharmacologic modulation of neutrophil functions. Clin Dermatol 2000;18:369-73
   PubMed Web of Science ®Google Scholar
• Schmidt E, Reimer S, Kruse N, The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 2001;124:157-62
   PubMed Web of Science ®Google Scholar
• Piette EW, Werth VP. Dapsone in the management of autoimmune bullous diseases. Immunol Allergy Clin North Am 2012;32:317-22
   PubMed Web of Science ®Google Scholar
• Tsuruta D, Ishii N, Hamada T, IgA pemphigus. Clin Dermatol 2011;29:437-42
   Google Scholar
• Monshi B, Richter L, Hashimoto T, IgA pemphigus of the subcorneal pustular dermatosis type. Successful therapy with a combination of dapsone and acitretin. Hautarzt 2012;63:482-6
   Google Scholar
• Tabrizi MN, Chams-Davatchi C, Esmaeeli N, Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial. J Eur Acad Dermatol Venereol 2007;21:79-84
   PubMed Web of Science ®Google Scholar
• Iraji F, Asilian A, Siadat AH. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol 2010;9:684-6
   Google Scholar
• Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003;131:48-52
   PubMed Web of Science ®Google Scholar
• Namazi MR. Nicotinamide in dermatology: a capsule summary. Int J Dermatol 2007;46:1229-31
   Google Scholar
• Iraji F, Banan L. The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of pemphigus vulgaris. Dermatol Ther 2010;23:308-11
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-72
   PubMed Web of Science ®Google Scholar
• Gurcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009;161:723-31
   PubMed Web of Science ®Google Scholar
• Ishikawa C, Tsuda T, Konishi H, Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. Antimicrob Agents Chemother 2009;53:1760-5
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Yilmaz E, Basaran E, Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus? Arch Dermatol 1995;131:1339-40
   PubMedGoogle Scholar
• Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 1993;28:998-1000
   PubMed Web of Science ®Google Scholar
• Kumar Mangalam A, Aggarwal A, Naik S. Gold sodium thiomalate (GSTM) inhibits lipopolysaccharide stimulated tumor necrosis factor-alpha through ceramide pathway. Cell Immunol 2002;219:1-10
   Google Scholar
• Pandya AG, Dyke C. Treatment of pemphigus with gold. Arch Dermatol 1998;134:1104-7
   PubMedGoogle Scholar
• Lange D, Meiss F, Fiedler E, Gold. Effective therapy for mucosal lesions of pemphigus vulgaris. Hautarzt 2007;58:142-5
   Google Scholar
• Iranzo P, Alsina MM, Martinez-De Pablo I, Gold: an old drug still working in refractory pemphigus. J Eur Acad Dermatol Venereol 2007;21:902-7
   Google Scholar
• Eisen D, Ellis CN. Topical cyclosporine for oral mucosal disorders. J Am Acad Dermatol 1990;23:1259-64
   PubMed Web of Science ®Google Scholar
• Hodgson TA, Malik F, Hegarty AM, Porter SR. Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. Eur J Dermatol 2003;13:142-4
   PubMed Web of Science ®Google Scholar
• Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010;302:241-53
   PubMed Web of Science ®Google Scholar
• Hiepe F, Pfuller B, Wolbart K, C1q: a multifunctional ligand for a new immunoadsorption treatment. Ther Apher 1999;3:246-51
   PubMedGoogle Scholar
• Wallukat G, Muller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002;347:1806
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Schmidt E. Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 2009;6:270-80
   PubMedGoogle Scholar
• Anhalt GJ, Labib RS, Voorhees JJ, Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982;306:1189-96
   PubMed Web of Science ®Google Scholar
• Amagai M, Karpati S, Prussick R, Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992;90:919-26
   PubMed Web of Science ®Google Scholar
• Amagai M, Hashimoto T, Green KJ, Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995;104:895-901
   PubMed Web of Science ®Google Scholar
• Zillikens D, Schmidt E, Reimer S, Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice. J Pathol 2001;193:117-24
   PubMed Web of Science ®Google Scholar
• Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Ther Apher Dial 2012;16:311-20
   Google Scholar
• Schmidt E, Klinker E, Opitz A, Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003;148:1222-9
   PubMed Web of Science ®Google Scholar
• Luftl M, Stauber A, Mainka A, Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003;149:598-605
   PubMedGoogle Scholar
• Shimanovich I, Herzog S, Schmidt E, Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006;31:768-74
   PubMedGoogle Scholar
• Shimanovich I, Nitschke M, Rose C, Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008;158:382-8
   PubMed Web of Science ®Google Scholar
• Behzad M, Mobs C, Kneisel A, Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012;166:844-52
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Shimanovich I, Meier M, Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012;166:154-60
   Google Scholar
• Zillikens D, Derfler K, Eming R, Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007;5:881-7
   PubMedGoogle Scholar
• Hollander N. Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol 2012;3:3
   Google Scholar
• Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366:2008-16
   PubMed Web of Science ®Google Scholar
• Mouquet H, Musette P, Gougeon ML, B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008;128:2859-69
   PubMed Web of Science ®Google Scholar
• Schmidt E, Brocker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008;34:56-64
   PubMed Web of Science ®Google Scholar
• Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003;149:899-901
   PubMedGoogle Scholar
• Eming R, Nagel A, Wolff-Franke S, Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008;128:2850-8
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9
   PubMed Web of Science ®Google Scholar
• Joly P, Mouquet H, Roujeau JC, A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-52
   PubMed Web of Science ®Google Scholar
• Nagel A, Podstawa E, Eickmann M, Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009;129:2202-10
   PubMed Web of Science ®Google Scholar
• Lunardon L, Tsai KJ, Propert KJ, Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 2012;148:1031-6
   PubMedGoogle Scholar
• Jensen AO, Moller BK, Vangkilde A, Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab. Br J Dermatol 2009;160:1359-61
   Google Scholar
• Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011;65:552-8
   PubMed Web of Science ®Google Scholar
• Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann NY Acad Sci 2009;1173:683-91
   PubMed Web of Science ®Google Scholar
• Leshem YA, Hodak E, David M, Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol 2012; doi: 10.1016/j.jaad.2012.08.010
   Google Scholar
• Horvath B, Huizinga J, Pas HH, Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012;166:405-12
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011;165:646-51
   PubMed Web of Science ®Google Scholar
• Tony HP, Burmester G, Schulze-Koops H, Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; doi: 10.1186/ar3337
   Google Scholar
• Kasperkiewicz M, Eming R, Behzad M, Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges 2012;10:727-32
   PubMed Web of Science ®Google Scholar
• Schmidt E, Hennig K, Mengede C, Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol 2009;132:334-41
   PubMed Web of Science ®Google Scholar
• Lunardon L, Payne AS. Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. J Allergy Clin Immunol 2012;130:800-3
   Google Scholar
• Hertl M, Zillikens D, Borradori L, Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008;6:366-73
   PubMed Web of Science ®Google Scholar
• Alter M, Wittmann M, Volker B, Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases. Hautarzt 2009;60:743-8
   Google Scholar
• Leuci S, Levine D, Zhang J, Razzaque Ahmed A. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells. G Ital Dermatol Venereol 2009;144:379-409
   PubMed Web of Science ®Google Scholar
• Menezes N, Leite I, Tente D, Pemphigus vulgaris–still a difficult disease to treat. Int J Dermatol 2010;49:230-2
   Google Scholar
• Strowd LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad Dermatol 2011;64:490-4
   PubMed Web of Science ®Google Scholar
• Craythorne E, du Viver A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med 2011;40:616-20
   Google Scholar
• Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2011;65:1064-5
   PubMed Web of Science ®Google Scholar
• Kim MR, Kim HC, Kim SC. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients. Dermatology 2011;223:182-8
   PubMed Web of Science ®Google Scholar
• Reguiai Z, Tabary T, Maizieres M, Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol 2012;67:623-9
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. Clinical trials database. Available from: http://www.clinicaltrials.gov [Last accessed 31 October 2012]
   Google Scholar
• German Clinical Trials Register. Available from: https://drks-neu.uniklinik-freiburg.de/drks_web [Last accessed 8 February 2013]
   Google Scholar
• Murrell DF, Dick S, Ahmed AR, Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58:1043-6
   PubMed Web of Science ®Google Scholar
• Rosenbach M, Murrell DF, Bystryn JC, Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009;129:2404-10
   PubMed Web of Science ®Google Scholar
• Heupel WM, Efthymiadis A, Schlegel N, Endothelial barrier stabilization by a cyclic tandem peptide targeting VE-cadherin transinteraction in vitro and in vivo. J Cell Sci 2009;122:1616-25
   Google Scholar
• Spindler V, Rotzer V, Dehner C, Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. J Clin Invest 2013; doi: 10.1172/JCI60139
   Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310
   PubMed Web of Science ®Google Scholar
• Mao X, Payne AS. Seeking approval: present and future therapies for pemphigus vulgaris. Curr Opin Investig Drugs 2008;9:497-504
   PubMedGoogle Scholar
• Aoki-Ota M, Kinoshita M, Ota T, Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J Invest Dermatol 2006;126:105-13
   PubMed Web of Science ®Google Scholar
• Payne AS, Siegel DL, Stanley JR. Targeting pemphigus autoantibodies through their heavy-chain variable region genes. J Invest Dermatol 2007;127:1681-91
   Google Scholar
• Moran E, Carbone F, Augusti V, Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol 2012;49:270-6
   PubMed Web of Science ®Google Scholar
• Oyama Y, Parker ER, Brieva J, High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory pemphigus foliaceus. Bone Marrow Transplant 2004;34:1097-8
   PubMed Web of Science ®Google Scholar
• Vanikar AV, Trivedi HL, Patel RD, Allogenic hematopoietic stem cell transplantation in pemphigus vulgaris: a single-center experience. Indian J Dermatol 2012;57:9-11
   Google Scholar